Free Trial

American Century Companies Inc. Has $102.96 Million Holdings in Natera, Inc. $NTRA

Natera logo with Medical background

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

American Century Companies Inc. cut its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 26.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 728,095 shares of the medical research company's stock after selling 267,277 shares during the quarter. American Century Companies Inc. owned about 0.54% of Natera worth $102,960,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in NTRA. Price T Rowe Associates Inc. MD grew its stake in shares of Natera by 134.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after buying an additional 3,871,862 shares in the last quarter. Nuveen LLC bought a new position in shares of Natera in the first quarter valued at $113,375,000. JPMorgan Chase & Co. grew its stake in shares of Natera by 9.9% in the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after buying an additional 660,538 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Natera by 8,233.5% in the first quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock valued at $56,270,000 after buying an additional 393,149 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of Natera by 13.7% in the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company's stock valued at $287,908,000 after buying an additional 245,719 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on NTRA. UBS Group raised their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Morgan Stanley reissued an "overweight" rating and issued a $195.00 target price on shares of Natera in a research note on Sunday, August 10th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 target price for the company in a research note on Monday, July 28th. Royal Bank Of Canada lifted their price objective on shares of Natera from $251.00 to $255.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $220.00 price objective (up from $210.00) on shares of Natera in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company's stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of "Buy" and an average target price of $193.19.

View Our Latest Stock Report on NTRA

Insider Buying and Selling

In other news, insider Solomon Moshkevich sold 875 shares of the business's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $136,027.50. Following the completion of the sale, the insider owned 123,859 shares of the company's stock, valued at approximately $19,255,120.14. The trade was a 0.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 5,807 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $132.88, for a total transaction of $771,634.16. Following the completion of the sale, the chief executive officer directly owned 163,593 shares of the company's stock, valued at approximately $21,738,237.84. The trade was a 3.43% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 61,792 shares of company stock valued at $9,227,972 in the last 90 days. 5.63% of the stock is currently owned by corporate insiders.

Natera Stock Up 0.8%

Shares of Natera stock traded up $1.31 during trading on Thursday, reaching $161.95. The company's stock had a trading volume of 993,653 shares, compared to its average volume of 1,519,047. The business's 50-day moving average price is $154.89 and its 200-day moving average price is $154.48. The firm has a market cap of $22.23 billion, a PE ratio of -84.79 and a beta of 1.76. Natera, Inc. has a 52 week low of $110.57 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company's revenue was up 32.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Company Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Further Reading

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Should You Invest $1,000 in Natera Right Now?

Before you consider Natera, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.

While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines